The FDA has granted breakthrough therapy designations for 25 new drugs while denying 32 applications as of Aug. 13. All parties, including the FDA and patient advocacy organizations, are hoping that patients with dire diseases get their hands on more effective drugs more quickly under the new drug designation, Dr. Patricia Fitzpatrick Dimond writes. "One of the best things about getting this breakthrough designation is that it drives patients to clinical trials, and it drives patients to the understanding that there is continued work being done," said trial investigator Dr. Omid Hamid.

Related Summaries